Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.

Journal:

Journal of Clinical Oncology

Published:

2025-11-26

DOI:

10.1200/jco-25-01153

Affiliations:

8

Authors:

12

Go to article

Institutions	Authors	Share
Fudan University Shanghai Cancer Center (FUSCC), China	4.000000	0.33
Shanghai Medical College (SHMC), Fudan University, China	2.000000	0.17
Chia Tai Tianqing Pharmaceutical Group Co. Ltd., China	2.000000	0.17
Hospital and Cancer Center, CQU, China	1.000000	0.08
Hunan Cancer Hospital, China	1.000000	0.08
Harbin Medical University Cancer Hospital, China	1.000000	0.08
Guizhou Cancer Hospital, Guizhou Medical University, China	1.000000	0.08

Interested in Oncology and Carcinogenesis?